This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Denali Q4 Earnings Beat Estimates, Hunter Syndrome Drug in Focus
by Zacks Equity Research
DNLI reports a narrower-than-expected loss for the fourth quarter of 2024. Denali remains on track to submit a BLA for tividenofusp alfa for the treatment of MPS II (Hunter syndrome).
Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
KYMR reports a wider-than-expected loss for the fourth quarter of 2024. The company expects the current cash balance to provide a runway into mid-2027.
Novavax Q4 Loss Narrower Than Expected, Sales Beat Estimates
by Zacks Equity Research
NVAX reports encouraging fourth-quarter results. It completes the sale of its Czech Republic manufacturing unit to Novo Nordisk for $200 million.
The Zacks Analyst Blog Highlights Merck, Sanofi, Regeneron and Ionis
by Zacks Equity Research
Merck, Sanofi, Regeneron and Ionis are included in this Analyst Blog.
Pharma Stock Roundup: EU Nod to MRK's Welireg, IONS' Q4 Results & More
by Kinjel Shah
EC approves MRK's Welireg for two indications. FDA grants priority review to SNY and REGN's Dupixent sBLA for bullous pemphigoid.
AstraZeneca Rises Almost 9% in a Month: How to Play the Stock
by Kinjel Shah
AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales in 2025.
BioMarin Q4 Earnings & Sales Top Estimates, Stock Up on Upbeat '25 View
by Zacks Equity Research
BMRN reports better-than-expected fourth-quarter results, driven by encouraging uptake for Voxzogo. It reiterates its guidance of generating $4 billion in total sales by 2027.
Novavax to Report Q4 Earnings: Here's What You Can Expect
by Zacks Equity Research
On NVAX's fourth-quarter earnings call, investors will likely focus on updates on its pipeline.
SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag
by Zacks Equity Research
The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025.
Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs
by Kinjel Shah
NVS and ABBV announce small M&A deals. FDA approves the expanded use of PFE and RHHBY's drugs.
AZN Q4 Earnings Lag, Sales Beat, Stock Up on China Probe Update
by Zacks Equity Research
AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business impact of the Chinese investigations remains minor.
GSK Beats on Q4 Earnings & Sales, Stock Up on Raised Long-Term Outlook
by Zacks Equity Research
GSK reports better-than-expected Q4 earnings. It also announces a new share buyback program and raises the long-term sales outlook for 2031 by $2 billion.
Regeneron Beats on Q4 Earnings, Initiates Quarterly Dividend
by Zacks Equity Research
REGN reports better-than-expected Q4 results. However, lead drug Eylea sales decline in the United States due to competition. The company initiates a dividend program,
MRK Gets Positive CHMP Nod for 21-Valent Pneumococcal Jab Capvaxive
by Zacks Equity Research
The Committee for Medicinal Products for Human Use recommends approval for Merck's pneumococcal 21-valent conjugate vaccine, Capvaxive.
Pharma Stock Roundup: SNY and RHHBY's Q4 Earnings & More
by Kinjel Shah
SNY and RHHBY announce fourth-quarter earnings. NVO's novel obesity medicine, amycretin, shows superior weight loss in study.
TEVA Stock Down 14% Despite Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Teva stock falls 14% despite better-than-expected fourth-quarter earnings results due to a weak 2025 outlook.
Sanofi Misses on Q4 Earnings & Sales, Expects Higher Profits in 2025
by Zacks Equity Research
SNY misses Q4 earnings and sales estimates. It expects earnings growth to rebound in 2025. It plans to buy back shares worth 5 billion euro in 2025.
Should AstraZeneca Stock Be in Your Portfolio Pre-Q4 Earnings?
by Zacks Equity Research
AZN's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected to have driven the company's top line.
EMA Accepts GSK's Filing for Depemokimab in Two Respiratory Diseases
by Zacks Equity Research
If approved, GSK's depemokimab will be the first ultra-long-acting biologic that requires only one dose every six months.
Pharma Stock Roundup: JNJ's Q4 Earnings, FDA Nod to AZN, Daiichi Drug
by Kinjel Shah
J&J announces Q4 earnings. FDA approves AZN and Daiichi's Dato-DXd for breast cancer.
SNY's Sarclisa Gets EU Nod for Expanded Use in Multiple Myeloma
by Zacks Equity Research
The latest decision makes Sanofi's Sarclisa the first anti-CD38 therapy for transplant-ineligible patients with front-line multiple myeloma in the EU.
Denali Gains 26.6% in a Year: How Should You Play the Stock?
by Zacks Equity Research
DNLI has had a good run in the past year on positive pipeline updates. A potential approval of its Hunter Syndrome drug should be a boost. However, recent pipeline setbacks warrant caution.
FDA Okays LLY's Omvoh for Second Inflammatory Bowel Disease Condition
by Zacks Equity Research
FDA approves Lilly's Omvoh for Crohn's disease, expanding its use to the second major type of IBD condition.
Kymera Provides Pipeline Objectives for 2025, Stock Gains
by Zacks Equity Research
KYMR outlines plans to advance its immunology candidates. As of Dec. 31, 2024, KYMR had $850 million in cash that should fund its operations into mid-2027.
Regeneron Reports Eylea Sales, Provides Other Pipeline Updates
by Zacks Equity Research
REGN announces business updates at the J.P. Morgan Healthcare Conference. The company also reports sales for Eylea and Eylea HD (on a preliminary basis).